Literature DB >> 8501948

Time-course of free radical activity during coronary artery operations with cardiopulmonary bypass.

S W Davies1, J P Duffy, D G Wickens, S M Underwood, A Hill, M F Alladine, R O Feneck, T L Dormandy, R K Walesby.   

Abstract

Myocardial and pulmonary impairment after cardiopulmonary bypass may be caused by oxygen free radicals produced by reperfusion and by activated neutrophils. Free radical activity was assessed by assays for lipid peroxidation (thiobarbituric acid-reactive material) and phospholipid-esterified diene conjugation (18:2[9,11]/18:2[9,12] molar ratio) in 25 patients during coronary artery operations. Arterial blood samples were obtained before, during the ischemic period, and for 24 hours thereafter. There were no significant changes in free radical indices during the ischemic periods, but after cessation of bypass they increased significantly. Ten minutes after bypass thiobarbituric acid-reactive material rose from 96 (median; range 65 to 145) nmol/gm albumin to 138 (85 to 200) nmol/gm albumin (p < 0.001), and molar ratio rose from 2.23% (0.45% to 7.70%) to 2.51% (0.39% to 7.93%) (p < 0.02). Values of thiobarbituric acid-reactive material subsequently decreased, but molar ratio reached a peak at 4 hours after bypass, 2.64% (0.55% to 10.08%) (p < 0.001), thereafter returning to baseline. The postoperative increases in thiobarbituric acid-reactive material and in molar ratio were correlated (r = +0.53; p = 0.006). These increases in thiobarbituric acid-reactive material and in molar ratio were not related to age, preoperative left ventricular function, or the number of grafts performed. Increase in thiobarbituric acid-reactive material correlated with the duration of cardiopulmonary bypass (r = +0.43; p = 0.03). In 10 patients in whom cardiopulmonary bypass was performed using a bubble oxygenator, the increases in thiobarbituric acid-reactive material were significantly greater than in the 15 in whom a membrane oxygenator was used (p < 0.02). These data show that after apparently uncomplicated coronary operations with bypass there is an increase in lipid peroxidation and diene conjugation, indicating increased free radical activity. This increase varies between patients and does not relate to patient or surgical factors but may depend on the type of oxygenator employed during bypass.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501948

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Potent antioxidative potential of propofol during cardiopulmonary bypass in the adult.

Authors:  S Zhang; S Yao
Journal:  J Tongji Med Univ       Date:  2001

2.  Protective effect of silymarin during coronary artery bypass grafting surgery.

Authors:  Tagreed Altaei
Journal:  Exp Clin Cardiol       Date:  2012

3.  Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation.

Authors:  Orfeas Liangos; Sophie Domhan; Christian Schwager; Martin Zeier; Peter E Huber; Francesco Addabbo; Michael S Goligorsky; Lynn Hlatky; Bertrand L Jaber; Amir Abdollahi
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

4.  High dose statin prophylaxis in cardiopulmonary bypass related surgery: clinical utility.

Authors:  Yie Roei Chee; R William G Watson; James McCarthy; Jehan Zeb Chughtai; Lars Nölke; David G Healy
Journal:  J Cardiothorac Surg       Date:  2017-03-31       Impact factor: 1.637

Review 5.  The inflammatory response to miniaturised extracorporeal circulation: a review of the literature.

Authors:  Hunaid A Vohra; Robert Whistance; Amit Modi; Sunil K Ohri
Journal:  Mediators Inflamm       Date:  2010-01-13       Impact factor: 4.711

6.  Dynamic changes in HMGB1 levels correlate with inflammatory responses during cardiopulmonary bypass.

Authors:  Zhiwei Zhang; Yuan Wu; Yuan Zhao; Xianzhong Xiao; Junwen Liu; Xinmin Zhou
Journal:  Exp Ther Med       Date:  2013-03-22       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.